PMID- 17503439
OWN - NLM
STAT- MEDLINE
DCOM- 20070917
LR  - 20070712
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 212
IP  - 4
DP  - 2007 Aug
TI  - Overexpression and gene amplification of BAG-1L in hormone-refractory prostate 
      cancer.
PG  - 395-401
AB  - BAG-1L (Bcl-2-associated anthanogene 1) has been found to interact with androgen 
      receptor (AR), and has been suggested to be involved in the development of 
      prostate cancer. In order to determine the presence of genetic and/or expression 
      alterations of BAG-1L in prostate cancer, we analysed human prostate cancer cell 
      lines and xenografts as well as patient samples of untreated, hormone-naive, and 
      hormone-refractory prostate carcinomas for sequence variations using denaturing 
      high-performance liquid chromatography (DHPLC), for gene copy number using 
      fluorescence in situ hybridization (FISH), and for expression using both 
      quantitative RT-PCR and immunostaining. Only one sequence variation was found in 
      all 37 cell lines and xenografts analysed. BAG-1 gene amplification was detected 
      in two xenografts. In addition, gene amplification was found in 6 of 81 (7.4%) 
      hormone-refractory clinical tumours, whereas no amplification was found in any of 
      the 130 untreated tumours analysed. Additionally, gain of the BAG-1 gene was 
      observed in 27.2% of the hormone-refractory tumours and in 18.5% of the untreated 
      carcinomas. In a set of 263 patient samples, BAG-1L protein expression was 
      significantly higher in hormone-refractory tumours than in primary tumours (p = 
      0.002). Altogether, these data suggest that amplification and overexpression of 
      BAG-1L may be involved in the progression of prostate cancer.
CI  - Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published 
      by John Wiley & Sons, Ltd.
FAU - Maki, H E
AU  - Maki HE
AD  - Cancer Genetics, Institute of Medical Technology, University of Tampere, and 
      Tampere University Hospital, FIN-33104 University of Tampere, Tampere, Finland.
FAU - Saramaki, O R
AU  - Saramaki OR
FAU - Shatkina, L
AU  - Shatkina L
FAU - Martikainen, P M
AU  - Martikainen PM
FAU - Tammela, T L J
AU  - Tammela TL
FAU - van Weerden, W M
AU  - van Weerden WM
FAU - Vessella, R L
AU  - Vessella RL
FAU - Cato, A C B
AU  - Cato AC
FAU - Visakorpi, T
AU  - Visakorpi T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (BCL2-associated athanogene 1 protein)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Cell Line, Tumor
MH  - Chromatography, High Pressure Liquid/methods
MH  - DNA Mutational Analysis/methods
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - Neoplasm Transplantation
MH  - Orchiectomy
MH  - Prostatic Neoplasms/genetics/*metabolism/pathology/therapy
MH  - RNA, Messenger/genetics
MH  - RNA, Neoplasm/genetics
MH  - Receptors, Androgen/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction/methods
MH  - Transcription Factors/genetics/*metabolism
MH  - Transplantation, Heterologous
MH  - Treatment Failure
EDAT- 2007/05/16 09:00
MHDA- 2007/09/18 09:00
CRDT- 2007/05/16 09:00
PHST- 2007/05/16 09:00 [pubmed]
PHST- 2007/09/18 09:00 [medline]
PHST- 2007/05/16 09:00 [entrez]
AID - 10.1002/path.2186 [doi]
PST - ppublish
SO  - J Pathol. 2007 Aug;212(4):395-401. doi: 10.1002/path.2186.